CO6640301A2 - Compuestos ologo-benzamida y su uso - Google Patents

Compuestos ologo-benzamida y su uso

Info

Publication number
CO6640301A2
CO6640301A2 CO12219956A CO12219956A CO6640301A2 CO 6640301 A2 CO6640301 A2 CO 6640301A2 CO 12219956 A CO12219956 A CO 12219956A CO 12219956 A CO12219956 A CO 12219956A CO 6640301 A2 CO6640301 A2 CO 6640301A2
Authority
CO
Colombia
Prior art keywords
ologo
benzamide compounds
compounds
benzamide
tris
Prior art date
Application number
CO12219956A
Other languages
English (en)
Spanish (es)
Inventor
Jung Mo Ahn
Ganesh Raj
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of CO6640301A2 publication Critical patent/CO6640301A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/56—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/64—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
    • C07C217/66—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/06—Compounds containing nitro groups bound to a carbon skeleton having nitro groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having carbon atoms of carboxamide groups, amino groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/08—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CO12219956A 2010-05-28 2012-12-04 Compuestos ologo-benzamida y su uso CO6640301A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34955510P 2010-05-28 2010-05-28

Publications (1)

Publication Number Publication Date
CO6640301A2 true CO6640301A2 (es) 2013-03-22

Family

ID=45004429

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12219956A CO6640301A2 (es) 2010-05-28 2012-12-04 Compuestos ologo-benzamida y su uso

Country Status (14)

Country Link
US (3) US20130231385A1 (enExample)
EP (1) EP2575453B1 (enExample)
JP (3) JP2013528174A (enExample)
KR (1) KR20130115108A (enExample)
CN (1) CN102958364A (enExample)
AU (1) AU2011258009B2 (enExample)
BR (1) BR112012030298A2 (enExample)
CA (1) CA2800811C (enExample)
CL (1) CL2012003322A1 (enExample)
CO (1) CO6640301A2 (enExample)
EA (1) EA201291460A1 (enExample)
MX (1) MX2012013855A (enExample)
SG (1) SG186076A1 (enExample)
WO (1) WO2011150360A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130231385A1 (en) 2010-05-28 2013-09-05 The Board Of Regents Of The University Of Texas Systems Oligo-benzamide compounds and their use
CA2840170A1 (en) * 2011-06-21 2012-12-27 The Johns Hopkins University Focused radiation for augmenting immune-based therapies against neoplasms
US8754124B2 (en) 2011-11-23 2014-06-17 Board Of Regents, The University Of Texas System Oligo-benzamide compounds and their use in treating cancers
US8835493B2 (en) 2011-11-23 2014-09-16 Board Of Regents, The University Of Texas System Oligo-benzamide compounds for use in treating cancers
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
AU2016264034B2 (en) * 2015-05-18 2020-03-05 KaNDy Therapeutics Limited Dual NK-1/NK-3 receptor antagonists for the treatment of sex-hormone-dependent diseases
CA2998170C (en) 2015-09-15 2023-10-03 Savage Medical, Inc. Devices and methods for anchoring a sheath in a tissue cavity
USD874674S1 (en) * 2016-10-17 2020-02-04 Brandcore Limited Vibrator
CA3121247A1 (en) * 2018-12-03 2020-06-11 Board Of Regents, The University Of Texas System Oligo-benzamide analogs and their use in cancer treatment
WO2023154856A1 (en) * 2022-02-11 2023-08-17 Board Of Regents, The University Of Texas System Oligo-benzamide analogs and their use in cancer treatment

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1903899A (en) 1933-04-18 Cabboxylic acid abylides oe the benzene sebies and process oe making
US3951914A (en) 1974-07-30 1976-04-20 E. I. Du Pont De Nemours And Company Process for preparing poly(1,4-benzamide) in cyclic sulfone media
US5212203A (en) 1986-01-21 1993-05-18 Centre International De Recherches Dermatogologiques (C.I.R.D.) Aromatic benzamido compounds; their preparation and their use in human or veterinary medicine or in cosmetic preparations
US5734081A (en) 1994-08-05 1998-03-31 Warner-Lambert Company Arylthio compounds
WO2001064642A2 (en) 2000-02-29 2001-09-07 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
US7355081B2 (en) * 2002-04-17 2008-04-08 The University Of North Carolina At Chapel Hill Curcumin analogues and uses thereof
EP1670483A4 (en) * 2003-09-10 2010-02-17 Merck & Co Inc 17-heterocyclic 4-azasteroid derivatives as androgen receptor modules
EP2392586A1 (en) 2004-02-20 2011-12-07 The Trustees of The University of Pennsylvania Binding peptidomimetics and uses of the same
WO2006086345A2 (en) 2005-02-07 2006-08-17 The Trustees Of Columbia University In The City Of New York Methods to treat or prevent hormone-resistant prostate cancer using sirna specific for protocadherin-pc, or other inhibitors of protocadherin-pc expression or activity
US20070129353A1 (en) 2005-11-08 2007-06-07 Michael Kahn Alpha-helix mimetics and method relating to the treatment of cancer stem cells
US8236983B2 (en) 2008-03-13 2012-08-07 Board Of Regents, The University Of Texas System Composition and method for the treatment of diseases affected by apoptosis
US7816324B2 (en) 2007-03-13 2010-10-19 Board Of Regents, The University Of Texas System Composition and method for the treatment of diseases affected by a peptide receptor
TWI469971B (zh) * 2007-10-26 2015-01-21 Univ California 二芳基乙內醯脲類化合物
BRPI0907754A2 (pt) 2008-02-08 2015-07-21 Aileron Therapeutics Inc Macrociclos peptidomiméticos terapêuticos
BRPI0907844B8 (pt) * 2008-02-22 2021-05-25 Radius Health Inc compostos e método para modular um receptor de andrógeno, processos de preparação e composição farmacêutica dos mesmos e seus usos
US8188098B2 (en) 2008-05-19 2012-05-29 Hoffmann-La Roche Inc. GPR119 receptor agonists
CN101643451B (zh) * 2008-08-07 2013-03-06 浙江海正药业股份有限公司 过氧化物酶增殖物激活受体亚型δ类激动剂化合物及其制备方法
MX2011004082A (es) 2008-10-17 2011-10-14 Dana Farber Cancer Inst Inc Peptidos de dominio citoplasmico muc-1 como inhibidores del cancer.
EP2391372A4 (en) 2009-01-30 2013-07-03 Bayer Healthcare Llc ESTROGENIC RECEPTOR-BASED CANCER TREATMENT METHODS BY INHIBITING X1 BOXING BINDING PROTEIN (XBP1)
BR112012009262A2 (pt) 2009-10-23 2019-09-24 Health Research Inc ''método para inibir a proliferação de células de câncer positivo para ar em um indivíduo diagnosticado com,ou qual se suspeita que tenha cânce positivo para ar e método para identificar se um indivíduo é um candidato para tratamento com uma composiçâo
US20130231385A1 (en) * 2010-05-28 2013-09-05 The Board Of Regents Of The University Of Texas Systems Oligo-benzamide compounds and their use
US8835493B2 (en) * 2011-11-23 2014-09-16 Board Of Regents, The University Of Texas System Oligo-benzamide compounds for use in treating cancers
US8754124B2 (en) 2011-11-23 2014-06-17 Board Of Regents, The University Of Texas System Oligo-benzamide compounds and their use in treating cancers

Also Published As

Publication number Publication date
EP2575453B1 (en) 2018-08-01
CA2800811A1 (en) 2011-12-01
BR112012030298A2 (pt) 2015-09-29
CA2800811C (en) 2019-02-26
SG186076A1 (en) 2013-01-30
EA201291460A1 (ru) 2013-11-29
JP2017019769A (ja) 2017-01-26
JP2018131459A (ja) 2018-08-23
JP2013528174A (ja) 2013-07-08
MX2012013855A (es) 2013-04-08
US20130231385A1 (en) 2013-09-05
AU2011258009A1 (en) 2013-01-10
US20160130217A1 (en) 2016-05-12
US10618869B2 (en) 2020-04-14
US9856206B2 (en) 2018-01-02
EP2575453A1 (en) 2013-04-10
US20180230087A1 (en) 2018-08-16
JP6385986B2 (ja) 2018-09-05
EP2575453A4 (en) 2015-12-23
KR20130115108A (ko) 2013-10-21
CL2012003322A1 (es) 2014-03-28
CN102958364A (zh) 2013-03-06
AU2011258009B2 (en) 2016-04-21
WO2011150360A1 (en) 2011-12-01

Similar Documents

Publication Publication Date Title
CO6321189A2 (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
CL2016001287A1 (es) Benzamidas sustituidas y procedimiento para su uso
CO7121325A2 (es) Nuevos diazaespirocicloalcanos y azaespirocicloalcanos
GT201700189A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
ECSP11011390A (es) Compuestos espiro-amidas sustituidas
NI201500167A (es) Compuestos químicos
CR9786A (es) Compuestos de bencimidazol-tiofeno
GT201400297A (es) Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen
UY34632A (es) Compuestos de oxazolidin- 2- ona y usos de los mismos
CL2012003415A1 (es) Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
UY34220A (es) Indazoles, composiciones farmacéuticas y uso de los mismos
GT201200165A (es) Triazolopiridinas
GT201400230A (es) Necleòsidos de espìrooxetano de uracilo
CO6410315A2 (es) Nuevos anticuerpos anti-alfa5beta1 y sus usos
ECSP17069696A (es) Compuestos novedosos
AR125920A2 (es) Composiciones que comprenden vortioxetina y donepezil
NI201500096A (es) Compuesto químicos
CO2018002211A2 (es) Piridinona dicarboxamida para su uso como inhibidores de bromodominio
MX2012013855A (es) Compuestos de oligobenzamida y su uso.
DOP2018000066A (es) Compuestos útiles para inhibir ror-gamma-t
UY32520A (es) Compuestos que tienen actividad agonista del receptor de glucocorticoesteroides
CY1118277T1 (el) Σταθερη φαρμακοτεχνικη μορφη πεξιγανανης
GT201300225A (es) Tieno (2,3-d) derivados de pirimidina y su uso para el tratamiento de la arritmia
ECSP13012679A (es) Composiciones farmacéuticas que comprenden alisporivir
CL2012001759A1 (es) Compuestos derivados de 8-hidroxiquinolina-7-carboxamida; composicion farmaceutica.

Legal Events

Date Code Title Description
FC Application refused